Kisunla is an injectable monoclonal antibody designed to slow cognitive decline in early symptomatic Alzheimer’s disease. It targets and helps clear amyloid plaques in the brain, a hallmark of the condition. Administered via intravenous infusion, this treatment is intended for adults with mild cognitive impairment or mild dementia, offering a potential path to preserve function longer.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends